-

Fujifilm Validates Cancer Cell-Targeting Potential of Peptide Oligonucleotide Conjugates with Novel Cyclic Peptides

Research highlights to be presented at TIDES USA 2025

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with cyclic peptides developed from Fujifilm’s proprietary peptide library, which contains trillions of variants. This research achievement will be presented at TIDES USA, an exhibition to be held from May 19 to 22, 2025, in San Diego (poster number: 35).

Cyclic peptides, including those containing unnatural amino acids, are emerging as a promising new modality in drug discovery due to their unique and favorable properties, including high binding affinity and specificity, improved tissue permeability, and synthetic versatility. Peptide-oligonucleotide conjugation addresses delivery challenges associated with oligonucleotide-based therapies by utilizing the excellent delivery properties of peptides and have been actively researched.

Leveraging its large peptide library constructed with mRNA display technology, and structural optimization techniques, Fujifilm has developed a proprietary cyclic peptide that binds strongly to integrins overexpressed on the surface of cancer cells, with a low dissociation constant (KD) of 1.6 nM. Utilizing chemical modification methods Fujifilm can successfully synthesize the peptide-oligonucleotide conjugate at high yield. Uptake of these peptide-oligonucleotide conjugates by cancer cells is higher compared to uptake of the non-conjugated oligonucleotide, demonstrating the peptide-oligonucleotide conjugate’s ability to selectively accumulate in cancer cells.

Fujifilm is expanding its drug discovery services for peptide therapeutics globally, providing a wide range of contract research services focusing on peptide discovery, high-throughput screening, and structural optimization. Fujifilm’s one-stop comprehensive service includes peptide chemical synthesis and target protein expression and purification to meet diverse research demands. Fujifilm is committed to driving research and development that fosters technological innovation in the healthcare field, leveraging the ability of cyclic peptides to regulate cellular functions and their specific molecular recognition capabilities, contributing to the advancement of pharmaceutical development of peptide therapeutics.

For more information please visit: Discovery Service of Diverse and High-Affinity Cyclic Peptides

Contacts

Media Contact
Christine Jackman
FUJIFILM Holdings America Corporation
E-mail: christine.jackman@fujifilm.com
Tel: +1-914-261-4959

Megan Augustine
FUJIFILM Holdings America Corporation
E-mail: megan.augustine.contractor@fujifilm.com

Other Contact
CRO Business Development Office
FUJIFILM Corporation
E-mail: dge-CRO-inq@fujifilm.com

FUJIFILM Corporation


Release Versions

Contacts

Media Contact
Christine Jackman
FUJIFILM Holdings America Corporation
E-mail: christine.jackman@fujifilm.com
Tel: +1-914-261-4959

Megan Augustine
FUJIFILM Holdings America Corporation
E-mail: megan.augustine.contractor@fujifilm.com

Other Contact
CRO Business Development Office
FUJIFILM Corporation
E-mail: dge-CRO-inq@fujifilm.com

More News From FUJIFILM Corporation

Fujifilm and Quantum Flex Pack to Present at Digital Packaging Summit: How "Mainstream" Is Being Mastered in Digital Flexible Packaging

SCHAUMBURG, Ill.--(BUSINESS WIRE)--FUJIFILM North America Corporation, Business Innovation Division, and Quantum Flex Pack will present together at Digital Packaging Summit, November 16-18 at the Hyatt Regency Coconut Point Resort and Spa in Bonita Springs, Florida. They will discuss how a digital inkjet press can move beyond short-run work and into mainstream flexible packaging production. Quantum Flex Pack, based in Rockford, Illinois, is the first company in the U.S. to purchase and install...

Fujifilm’s ALIGN Program Enables Print Service Providers To Deliver Consistent, Repeatable Color

SCHAUMBURG, Ill.--(BUSINESS WIRE)--FUJIFILM North America Corporation, Business Innovation Division, today announces the introduction of its ALIGN program, a consulting-based print excellence program that combines decades of Fujifilm print expertise with a structured, on-site process to help print businesses achieve consistent, repeatable color across presses (of various brands), operators, shifts, devices, and production environments. “The Fujifilm ALIGN program leverages decades of Fujifilm’s...

Create With Us: On Tour - Fujifilm Brings Its Flagship Community Event to Creators Nationwide

VALHALLA, N.Y.--(BUSINESS WIRE)--FUJIFILM North America Corporation, Electronic Imaging Division, announces the upcoming Create With Us: On Tour, bringing its flagship community event to cities across the country. Running from late 2026 into 2027, the tour gives Fujifilm’s focused demographics - traditional photographers, new users, creators, and cinematographers - the opportunity to develop their skills and connect with fellow creatives from their community. Create With Us began in Seattle in...
Back to Newsroom